Next Science shares defy ASX market slump to surge 8%

Next Science shares are set to finish Thursday’s trading session on a high note.

| More on:
Rising arrow on a blue graph symbolising a rising share price.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Next Science shares leap 8.54% to 89 cents during mid-afternoon trade 
  • The company announced a multi-year distribution agreement with Oraderm Pharmaceuticals 
  • Under the deal, BlastX will be sold and marketed across Australia and New Zealand from the second half of 2022 

The Next Science Ltd (ASX: NXS) share price is roaring higher today despite the ASX being deep in the red.

At the time of writing, the medical technology company’s shares are fetching at 89 cents a pop, up 8.54%.

In contrast, the All Ordinaries Index (ASX: XAO) is trading at 7,318.5 points, down 1.46%.

Next Science expands ‘commercial footprint’

Investors are buying up the Next Science share price after the company revealed a positive update to the market.

In its release, Next Science advised it has signed a multi-year distribution agreement with Oraderm Pharmaceuticals to sell BlastX.

Located in Cremone, Victoria, Oraderm Pharmaceuticals is a medical sales joint venture between Douglas Pharmaceuticals and Arrotex Pharmaceuticals.

Under the deal, Oraderm will have exclusive rights across Australia and New Zealand for the sale and marketing of BlastX. However, this will be a dual Next ScieUnce/Oraderm labelled version. 

Next Science is expected to receive a portion of revenues based on an agreed unit price and a minimum quantity per order.

The agreement will run for a period of five years but can be extended for another three years.

Oraderm’s initial focus in Australia will be hospitals, nursing homes, dermatologists and over-the-counter pharmacy sales.

In New Zealand, Oraderm will concentrate on wound care in hospitals and other clinical settings accommodating varied distribution solutions.

Next Science is scheduled to deliver training to the distributor’s sales force teams in late June. Commercial sales in Australia and New Zealand are expected to commence during the second half of 2022.

Next Science managing director, Judith Mitchell commented:

We are delighted to expand our commercial footprint for BlastX in Australia and New Zealand through Oraderm.

Oraderm is a well-known brand within the healthcare industry with a track record of success in bringing new products to market. This partnership enhances our ability to offer our proven wound care product to healthcare professionals and patients in Australia and New Zealand as we continue to pursue our mission to heal patients and save lives worldwide by reducing the impacts of biofilms on human health.

Next Science share price summary

Over the past 12 months, the Next Science share price has continued to tread lower to post a loss of 46%.

It’s worth noting that the company’s share price hit a fresh 52-week low of 79.5 cents in late April.

Based on valuation grounds, Next Science presides a market capitalisation of roughly $177.74 million.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Next Science Limited. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

What’s the outlook for the CSL share price in July?

We take a look at what the experts are saying about the biotech company's shares.

Read more »

Photo of a group of scientists cheering while working in a lab as the Race Oncology share price skyrockets today on positive study results
Healthcare Shares

Why is the Race Oncology share price soaring 13% today?

New trial results have excited ASX investors.

Read more »

Rising arrow on a blue graph symbolising a rising share price.
Healthcare Shares

Starphama share price lunges 5% on product relaunch

Early support for Starphama on Thursday has it off to a great start.

Read more »

Man with rocket wings which have flames coming out of them.
Healthcare Shares

Why is the Paradigm share price rocketing 20% higher today?

The Paradigm share price is having a very strong day...

Read more »

A businessman presents a company annual report in front of a group seated at a table
Healthcare Shares

Own Immutep shares? Here are 3 takeaways from the company’s investor update

Investors were mute to the update.

Read more »

A health professional wearing a stethoscope and scrubs shrugs with uncertainty.
Healthcare Shares

Has CSL been growing its dividend?

Is the biotech giant still increasing its dividends in a post-COVID world?

Read more »

Man pointing an upward line on a bar graph symbolising a rising share price.
Healthcare Shares

Why is the 4DMedical share price exploding 40% today?

4DMedical signed a three-year, nationwide contract with I-MED Radiology Network.

Read more »

Two medical researchers in white coats collaborate over a computer screen of data in a medical research laboratory
Healthcare Shares

What was the Sonic Healthcare share price when it first listed on the ASX?

Sonic Healthcare has an interesting history...

Read more »